Amer Joseph

Amer Joseph serves as the Vice President and Head of Global Clinical Development at Chiesi Group, leading a team of approximately 200 professionals dedicated to advancing respiratory, neonatology, and cardiovascular medicine. Previously, Amer held the position of VP and Global Head of Clinical Development for Rare Diseases R&D, where leadership contributed to achieving FDA and EMA approvals for multiple biologic therapeutics in 2023. Prior experience includes serving as Global Clinical Leader at Bayer, directing clinical strategies for major drug development programs in cardiology and nephrology, notably overseeing the pivotal Phase 3 studies of finerenone. Earlier roles at GSK and Bayer Pharmaceuticals involved significant contributions to clinical development in various therapeutic areas, including rare diseases and cardiovascular medicine. Amer's career began as a Physician in Cardiology and Internal Medicine within the NHS. Educational credentials include an MBBS in Medicine and a BSc in Neuroscience, both from UCL.